PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

The UAB-SCIMS offers a series of Fact Sheets on selected topics related to SCI. Some Fact Sheets are products of the University of Alabama at Birmingham Spinal Cord Injury Model System (UAB-SCIMS).

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

Based on data from its AReSVi-006 trial, the British vaccine maker said Arexvy, compared to a placebo, led to an overall ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Yarilet Perez is an experienced multimedia journalist and fact-checker with a Master of ... The Fed uses its balance sheet to help it accomplish those goals. The Fed decides what assets it holds ...

With the arrival of fall also comes the arrival of respiratory illness season, a time when many are at increased risk of ...

People who live in states that observe daylight saving time will see more daylight in the mornings and darker evenings as we “fall back.” Many VERIFY readers have sent us questions about ...

Total vaccine sales were down due to lower sales of Arexvy and Shingrix ... We have a strong balance sheet, which provides optionality to accelerate further growth organically and through business ...